BioWorld

May 29, 2009

Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi

If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today) Read More

Phase II Trial Update Triggers Wild Ride for Peregrine Shares

'Finished' Mouse Genome Is Still a Work in Progress

As Markets Brighten, Medivation Seeks $65.8M in Shares Offering

Neuropharm Revives Autism Drug, Rises on Partner Talks

Amylin 'Back to Business' Following Contentious Vote

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...